Best stock ideas for September 7

The author believes Hingham Institution for Savings (HIFS) represents a compelling investment opportunity due to its dual growth strategy targeting deposits and loans in existing affluent markets, which allows the bank to leverage its knowledge and relationships while mitigating expansion risks. The author also points to HIFS's long-tenured management team and significant insider ownership, including a CEO stake worth 16x his salary, as signals of deep commitment to long-term shareholder value. While HIFS has faced some recent challenges with interest rate sensitivity, the author notes its historical excellence in net interest margin and loan quality stemming from its conservative lending approach. The author's valuation analysis, incorporating metrics like ROA and price-to-book, indicates an expected 20.4% annual return. Given the growth strategy, aligned management incentives, and attractive valuation, the author sees HIFS as an excellent investment opportunity, despite risks including personnel dependence, interest rate fluctuations, and local economic conditions.

Read the full article here (5 free per month). Read time: 9 min

The author believes Catalent (CTLT) is an attractive investment opportunity as the contract manufacturing company transitions to a post-COVID environment focused on advanced biologics and gene therapies. The author upgraded CTLT to Buy based on an upbeat fiscal 2024 outlook projecting strong biologics growth and margin improvement from operational initiatives. CTLT also added independent directors as part of an agreement with activist Elliott Management to review strategic options. CTLT is gaining manufacturing business for promising new drugs like Novo Nordisk's Wegovy weight loss treatment. The author sees favorable long-term growth drivers from gene therapies like Sarepta's Duchenne muscular dystrophy drug that CTLT produces. With the stock at 24.7x the author's 2025 EPS estimate, valuation looks attractive for the growth opportunities. Risks include regulatory oversight and integration challenges with acquisitions, but the author is bullish on CTLT's outlook.

Read the full article here (paywall). Read time: 5 min

The author is bullish on Advanced Micro Devices, Inc. (AMD) primarily due to its promising data center guidance and opportunities in the AI sector. The company forecasts a 35% increase in data center revenue for the upcoming quarter, significantly bolstered by sales of its MI300A and MI300X processors. While AMD has experienced a slight dip in server CPU unit sales, this loss is offset by increased average selling prices and robust gaming revenue. Moreover, AMD has signaled confidence in its AI roadmap, particularly with strong customer interest in its MI300X processor, which has the potential to drive sustained growth in the data center sector. Financially, applying a conservative 22X multiple, the author suggests the stock could trade around $160, offering approximately 50% upside from its current trading price. AMD's varied product portfolio, ranging from data centers to gaming, positions it well to tap into the rapidly growing AI market, estimated to have a $150 billion Total Addressable Market by 2027. While acknowledging potential risks like margin erosion due to competition from Intel and production transition challenges, the author concludes that AMD's alignment with AI trends and expansive product portfolio make it a favorable candidate for future growth.

Read the full article here (5 free per month). Read time: 6 min

The author is bullish on KVH Industries. They argue that the stock is highly undervalued, trading at approximately 2.3x its 2023 EBITDA and near its 52-week low. The valuation appears even more compelling given that the company holds over $71 million in cash with no debt. The author highlights the sparse and arguably misguided analyst coverage, where the sole analyst's EBITDA projections for 2024 are 70% below the company's own 2023 guidance. They note that KVH has a strong competitive advantage with its satellite services, particularly in the commercial shipping sector, which makes up about 80% of the company’s business. While Low Earth Orbit (LEO) services like SpaceX's Starlink offer some competition, they are not reliable enough for deep-sea commercial users, which is KVH’s core market. The company is also shifting towards a "Connectivity as a Service" model, thereby reducing costs and increasing recurring revenues. Additionally, private equity firm Black Diamond owns about 17% of KVH and has a board seat, further hinting at potential acquisition opportunities. The author suggests that KVH is ripe for a share repurchase program, bolstering their case with a target price of $15.95 per share based on potential acquisition value. Overall, they see multiple avenues for stock price appreciation and consider the company a strong buy candidate.

Read the full article here (paywall). Read time: 7 min

Marvell Technology (MRVL) is a semiconductor company. The author believes MRVL is positioned for increased sales and profit momentum over time, despite current macro volatility, thanks to its expanding presence in AI and other key growth markets. MRVL recently delivered fiscal Q2 results that beat guidance, though the stock fell as Q3 outlook was in-line. The author notes MRVL has successfully integrated past acquisitions, refreshing its product portfolio. MRVL is forecasting a rebound after a likely negative Q3. The author sees MRVL shares as undervalued based on strong long-term cash flow potential. A $75 price target is reiterated, implying 30% upside. MRVL offers a modest dividend yield near 0.5%. Risks include high valuation multiples, customer concentration, and challenges with large acquisitions. But the author is bullish on MRVL's prospects.

Read the full article here (paywall). Read time: 10 min

The author is bullish on Myomo (NYSE:MYO), primarily due to recent favorable policy changes by the Centers for Medicare & Medicaid Services (CMS). After struggling for 11 years to gain broad insurance coverage for its MyoPro devices, CMS has now included these devices as a covered product under Medicare and started paying initial claims. This policy change is expected to dramatically increase Myomo's revenue, as previously only 1 in 10 patients enrolled in their pipeline actually received a device due to poor insurance coverage. With broad CMS coverage, the author estimates that Myomo could generate approximately $75 million in annual revenue from the 400 patients it adds to its pipeline each quarter. Additionally, the author highlights the company's relatively low market cap of less than $30 million, suggesting significant upside potential. A valuation of just $100 million would lead to a $3.00 share price, whereas the author believes the company should be trading closer to a $200 million equity value. Despite Myomo's current cash burn rate of $2.7 million per quarter, the author expects the company to become profitable by Q4 of next year due to improved reimbursements. Risks include potential delays in CMS policy implementation and the possibility of unnecessary and dilutive financings, but the author considers these risks mitigated by Myomo's commercial viability and insider stock purchases.

Read the full article here (5 free per month). Read time: 5 min